BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 25924622)

  • 1. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
    Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
    Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
    Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
    Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
    Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein domains of APOL1 and its risk variants.
    Lan X; Wen H; Lederman R; Malhotra A; Mikulak J; Popik W; Skorecki K; Singhal PC
    Exp Mol Pathol; 2015 Aug; 99(1):139-44. PubMed ID: 26091559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells.
    Cheng D; Weckerle A; Yu Y; Ma L; Zhu X; Murea M; Freedman BI; Parks JS; Shelness GS
    J Lipid Res; 2015 Aug; 56(8):1583-93. PubMed ID: 26089538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.
    Sharma AK; Friedman DJ; Pollak MR; Alper SL
    FEBS J; 2016 May; 283(10):1846-62. PubMed ID: 26945671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.
    Olabisi OA; Zhang JY; VerPlank L; Zahler N; DiBartolo S; Heneghan JF; Schlöndorff JS; Suh JH; Yan P; Alper SL; Friedman DJ; Pollak MR
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):830-7. PubMed ID: 26699492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking the 5' splice site of exon 4 by a morpholino oligomer triggers APOL1 protein isoform switch.
    Cheatham AM; Davis SE; Khatua AK; Popik W
    Sci Rep; 2018 Jun; 8(1):8739. PubMed ID: 29880816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tripartite complex of suPAR, APOL1 risk variants and α
    Hayek SS; Koh KH; Grams ME; Wei C; Ko YA; Li J; Samelko B; Lee H; Dande RR; Lee HW; Hahm E; Peev V; Tracy M; Tardi NJ; Gupta V; Altintas MM; Garborcauskas G; Stojanovic N; Winkler CA; Lipkowitz MS; Tin A; Inker LA; Levey AS; Zeier M; Freedman BI; Kopp JB; Skorecki K; Coresh J; Quyyumi AA; Sever S; Reiser J
    Nat Med; 2017 Aug; 23(8):945-953. PubMed ID: 28650456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disrupted apolipoprotein L1-miR193a axis dedifferentiates podocytes through autophagy blockade in an APOL1 risk milieu.
    Kumar V; Ayasolla K; Jha A; Mishra A; Vashistha H; Lan X; Qayyum M; Chinnapaka S; Purohit R; Mikulak J; Saleem MA; Malhotra A; Skorecki K; Singhal PC
    Am J Physiol Cell Physiol; 2019 Aug; 317(2):C209-C225. PubMed ID: 31116585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes.
    Kruzel-Davila E; Shemer R; Ofir A; Bavli-Kertselli I; Darlyuk-Saadon I; Oren-Giladi P; Wasser WG; Magen D; Zaknoun E; Schuldiner M; Salzberg A; Kornitzer D; Marelja Z; Simons M; Skorecki K
    J Am Soc Nephrol; 2017 Apr; 28(4):1117-1130. PubMed ID: 27864431
    [No Abstract]   [Full Text] [Related]  

  • 12. RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes.
    Bundy JL; Anderson BR; Francescatto L; Garrett ME; Soldano KL; Telen MJ; Davis EE; Ashley-Koch AE
    PLoS One; 2019; 14(6):e0217042. PubMed ID: 31158233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
    Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?
    Olabisi O; Al-Romaih K; Henderson J; Tomar R; Drummond I; MacRae C; Pollak M
    Clin Nephrol; 2016 Supplement 1; 86 (2016)(13):114-118. PubMed ID: 27509583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
    Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
    Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
    Gutiérrez OM; Judd SE; Irvin MR; Zhi D; Limdi N; Palmer ND; Rich SS; Sale MM; Freedman BI
    Nephrol Dial Transplant; 2016 Apr; 31(4):602-8. PubMed ID: 26152403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.
    Mikulak J; Oriolo F; Portale F; Tentorio P; Lan X; Saleem MA; Skorecki K; Singhal PC; Mavilio D
    Retrovirology; 2016 Sep; 13(1):63. PubMed ID: 27599995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOL1 toxin, innate immunity, and kidney injury.
    Limou S; Dummer PD; Nelson GW; Kopp JB; Winkler CA
    Kidney Int; 2015 Jul; 88(1):28-34. PubMed ID: 25853332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.
    Hu CA; Klopfer EI; Ray PE
    FEBS Lett; 2012 Apr; 586(7):947-55. PubMed ID: 22569246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.
    Bruggeman LA; Wu Z; Luo L; Madhavan SM; Konieczkowski M; Drawz PE; Thomas DB; Barisoni L; Sedor JR; O'Toole JF
    J Am Soc Nephrol; 2016 Dec; 27(12):3600-3610. PubMed ID: 27026370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.